Alector priced an underwritten public offering of 36,600,000 shares of common stock at $2.05 per share. The transaction is expected to generate gross proceeds of approximately $75 million before deducting underwriting discounts and other offering expenses. All shares are being sold by the company, with Morgan Stanley & Co. LLC and BTIG, LLC serving as joint lead book-running managers. The offering includes participation from new and existing investors such as TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Closing is expected on October 19, 2026, subject to customary conditions. Alector is a biotechnology company focused on developing therapies for neurodegenerative diseases.
